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The primary aim of breast cancer screening is to reduce breast cancer mortality, but screening also has negative side-effects
as overdiagnosis. To evaluate a screening programme, both benefits and harms should be considered. Published estimates of
the benefit-to-harm ratio, the number of breast cancer deaths prevented divided by the number of overdiagnosed breast can-
cer cases, varied considerably. The objective of the study was to estimate the benefit-to-harm ratio of breast cancer screening
in Denmark. The numbers of breast cancer deaths prevented and overdiagnosed cases [invasive and ductal carcinoma in situ
(DCIS)] were estimated per 1,000 women aged 50–79, using national published estimates for breast cancer mortality and
overdiagnosis, and national incidence and mortality rates. Estimations were made for both invited and screened women.
Among 1,000 women invited to screening from age 50 to age 69 and followed until age 79, we estimated that 5.4 breast
cancer deaths would be prevented and 2.1 cases overdiagnosed, under the observed scenario in Denmark of a breast cancer
mortality reduction of 23.4% and 2.3% of the breast cancer cases being overdiagnosed. The estimated benefit-to-harm ratio
was 2.6 for invited women and 2.5 for screened women. Hence, 2–3 women would be prevented from dying from breast can-
cer for every woman overdiagnosed with invasive breast cancer or DCIS. The difference between the previous published ratios
and 2.6 for Denmark is probably more a reflection of the accuracy of the underlying estimates than of the actual screening
programmes. Therefore, benefit-to-harm ratios should be used cautiously.
The primary aim of breast cancer screening is to reduce
breast cancer mortality. Other beneﬁts include more conser-
vative treatment and the positive psychological effect of
knowing that a negative test is associated with a reduced
breast cancer risk. But screening also has negative side-effects
as overdiagnosis, that is, a diagnosis of breast cancer that
would in the absence of screening not have led to clinically
manifest disease in the woman’s lifetime. Further harms to be
considered are longer time as a cancer patient due to the lead
time, false positive and false negative tests, radiation exposure,
negative psychological effects in terms of anxiety about waiting
for the mammogram report and the false reassurance to
women later diagnosed with interval cancers, Figure 1.
To evaluate a screening programme, both the beneﬁts and
harms should be considered. However, it is difﬁcult to weight all
beneﬁts and harms at the same time because they are measured
in very diverse ways. It has, therefore, become an established
procedure to report a beneﬁt-to-harm ratio, which is the number
of breast cancer deaths prevented divided by the number of
overdiagnosed breast cancer cases. It should be noted that both
indicators can be measured only at the population level, as it is
not possible to identify the individual woman with a prevented
breast cancer death or with an overdiagnosed breast cancer.
In 2012, the EUROSCREEN group estimated that for
every 1,000 women screened, 7 to 9 breast cancer death
would be prevented, and 4 cases would be overdiagnosed,
giving a ratio between 1.8 and 2.3.1 Using the same method-
ology, Hofvind et al. found a beneﬁt-to-harm ratio of 0.7 for
women screened in the Norwegian Breast Cancer Screening
Program.2 The published estimates of the beneﬁt-to-harm
ratio have thus varied considerably.
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In Denmark, population based breast cancer screening
was implemented in the Copenhagen municipality on April
1, 1991 and in the Funen county on November 1, 1993.
Together, these programmes covered 20% of Danish women.
Nationwide implementation of screening took place from the
late 2007 to 2010. We found implementation of screening to
be followed by a 25% decrease in breast cancer mortality in
Copenhagen3 and by a 22% decrease in Funen.4 We found
overdiagnosis, including invasive and ductal carcinoma in
situ (DCIS), to account for 2.3% of the breast cancer cases in
Copenhagen and Funen.5 This article aims to estimate the
beneﬁt-to-harm ratio of breast cancer screening in Denmark
using the long-term cohort data on the screening outcomes.
Methods
In Denmark, breast cancer screening targets women aged 50–
69 years with biennial invitations, initially using one-or two
view(s) mammography and later two views only. All mam-
mograms are read independently by two radiologists.
We assumed screening to affect the incidence and mortal-
ity from breast cancer in the age group 50–79 years.6 The
estimates of breast cancer mortality reduction and overdiag-
nosis were extracted from our previous studies, which used
the difference-in-differences method based on four cohorts
with individual follow-up data.3–5 The methodology pre-
sented by the EUROSCREEN group was used to estimate the
number of breast cancer deaths prevented and the number of
overdiagnosed cases.1 As the EUROSCREEN group estima-
tion is based on cumulative rates for age 50 to 79, the results
of our present study will differ from our previously published
estimates on number of breast cancer deaths prevented4 and
on number of overdiagnosed cases5 using other methods.
The results were presented for every 1,000 women aged 50
years invited to screening until age 69 years and followed
until age 79 years.
Estimates on breast cancer mortality reduction and
overdiagnosis
Estimates were derived from observational studies of birth
cohorts of women targeted by breast cancer screening. Three
control groups were used: a regional control group including
the same birth cohorts from the areas of Denmark where
screening had not yet been implemented; a historical control
group including birth cohorts from screening areas prior to
screening; and ﬁnally a historical, regional control including
birth cohorts from non-screening areas prior to screening.
Individual-level data and incidence-based mortality analysis
were used. The methodology was a difference-in-differences
analysis. The result of this analysis is a ratio of rate ratios.
This means that it estimated the change from before to dur-
ing screening in the screening area, controlled for the change
over this time period in the non-screening areas. In this way,
it estimated the effect of screening controlled for both
regional and time related differences in breast cancer risk.
In Copenhagen, a decrease in breast cancer mortality of
25% (95% conﬁdence interval (CI): 11 to 37%) was found for
invited women and of 37% for screened women after control-
ling for selection bias.3 In Funen, the decrease in breast can-
cer mortality for women invited to screening was 22% (95%
CI: 11 to 32%) and 28% (95% CI: 13 to 41%) for screened
women.4 We used person-years accumulated during the ﬁrst
ten years of the respective screening programmes for calcula-
tion of weighted estimates. Copenhagen contributed 430,823
person-years and Funen 514,556 person-years.3,4 This gave a
weighted estimated effect for invited women of 23.4% (5
[(430,823 3 25%)1 (514,556 3 22%)]/(430,8231 514,556)).
For screened women, the ﬁgure became 32.1% (5 [(430,823
3 37%)1 (514,556 3 28%)]/(430,8231 514,556)).
Overdiagnosis was estimated, in the Njor et al. article,5 as
the cumulative incidence of breast cancer in a screening
region compared with the expected cumulative incidence in
the absence of screening. The expected incidence in the
absence of screening was estimated from the incidence in the
historical control group (including women living in a screen-
ing area in the period before screening) controlled for the
change in incidence from before to after screening time in
the national control group (including women living outside
any screening area). It was assumed that the observed num-
ber of incident breast cancer cases followed a Poisson distri-
bution. The overdiagnosis estimate was calculated with a
Poisson regression analysis which is a standard method for
comparison of incidence rates. Njor et al.5 included period
(before or after screening), area (in or outside any screening
area), exposure to screening (yes or no), and 2-year birth
cohort in the analysis. This resulted in an effect of screening,
measured as a ratio of rate ratios, on the cumulative breast
cancer incidence of 1.023 (95% CI: 0.97 to 1.08). The lower
limit of the CI thus corresponded to a 3% reduction in the
cumulative incidence of breast cancer in invited as opposed
to non-invited women. While this makes sense as long as we
What’s new?
Breast cancer screening reduces breast cancer mortality, but one negative side-effect is overdiagnosis. Published estimates of
the benefit-to-harm ratio–the number of prevented breast cancer deaths divided by the number of overdiagnosed breast can-
cer cases–vary considerably. This study reports a benefit-to-harm ratio of 2.6 for women invited to breast cancer screening in
Denmark. Among 1,000 invited women from age 50 and followed up until 79, 2–3 women would be prevented from dying
from breast cancer for every overdiagnosed woman. International variations in benefit-to-harm ratios probably reflect differ-
ences in the accuracy of underlying estimates more than differences between screening programmes.
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talk about the cumulative incidence, it may seem strange to
have a negative estimate of overdiagnosis. Therefore, we have
reported this lower limit as 1, meaning no overdiagnosis.
For overdiagnosis for invited women, we used the increase
in the pooled cumulative incidence of breast cancer (invasive
and DCIS) of 2.3% (95% CI: 23 to 8%) reported by Njor
et al.5 For screened women, overdiagnosis amounted to 1%
in Funen and to 5% in Copenhagen according to Njor et al.5
Person-years of women not followed beyond screening age
are not relevant for estimation of overdiagnosis. Therefore, to
pool the estimates from Copenhagen and Funen, we weighted
them with the person-years reported for all women in the
Njor study. Copenhagen contributed 456,499 person-years
and Funen 323,363 person-years.5 This gave a weighted esti-
mate for screened women of 3.3% (5 [(456,499 3
5%)1 (323,363 3 1%)]/(456,4991 323,363)).
Measures of cumulative risk of breast cancer and breast
cancer death in absence of screening
Cumulative risk of breast cancer (invasive1DCIS) and
cumulative risk of breast cancer death from 50 to 79 years in
the absence of screening were computed. These risks were
expressed as the probability that a woman was diagnosed
with breast cancer (invasive or DCIS) or died from the dis-
ease between ages 50 and 79 in the absence of screening.
From NORDCAN,7 we extracted the age-speciﬁc breast can-
cer (invasive only) incidence and mortality rates for Danish
women aged 50–79 years in the 1996–2000 (i.e., before the
programme started in regions outside Copenhagen and
Funen). The cumulative risk of breast cancer was 8.8%, and
assuming an increase due to DCIS of 2.8%5, it became 9.1%.
The cumulative risk of breast cancer death was 3.4%. Thus,
among 1,000 women, we estimated 91 breast cancer (invasi-
ve1DCIS) cases and 34 breast cancer deaths (18 among
women aged 50–69 years and 16 among those aged 70–79;
Table 1).
Based on data used by Olsen et al.3 21% of breast cancer
deaths occurring in women aged 50–69 derived from breast
cancer diagnosed before age 50, thus before the women were
invited to screening. 51% of deaths from breast cancer in
women aged 70–79 derived from breast cancer diagnosed
under age 50 or over age 69. In these cases, breast cancer
screening could not have inﬂuenced the probability of dying
from breast cancer. Thus, the number of breast cancer death
occurring at aged 50–79 in which screening may have had a
protective effect was 22 of 34 (5 18 3 (1–0.21)1 16 3 (1–
0.51)) (Table 1).
In 1996–2000, breast cancer screening programmes were
already implemented for the 20% of Danish women living in
Copenhagen and Funen. Thus, we estimated the expected
cumulative risk of breast cancer in the absence of screening
(A) by subtracting from the estimated 91 breast cancer cases
an extra 2.3% for the 20% of women coming from Copenha-
gen and Funen (A5 91 – (0.2 3 A 3 0.023)) (Table 1). We
estimated the expected cumulative risk of breast cancer mor-
tality in the absence of screening (B) by adding to the esti-
mated 22 breast cancer deaths an extra 23.4% for the 20% of
the population coming from Copenhagen and Funen
(B5 221 (0.2 3 B 3 0.234)) (Table 1).
Hence, in the absence of screening, the expected numbers
of breast cancers and breast cancer deaths potentially affected
by screening were 90.6 and 23.1 per 1,000 women aged 50–
79 (Table 1). For screened women, the ﬁgures were 90.4 and
23.5 per 1,000 women aged 50–79 (Table 1).
Effect of screening
We estimated the effect of screening as the difference
between the estimated risks of breast cancer and breast can-
cer death assuming nationwide screening coverage, and the
expected risks in the absence of screening. The numbers of
breast cancer deaths prevented and overdiagnosis cases (inva-
sive and DCIS) were estimated per 1,000 women aged 50–79,
along with estimates using lower and upper points of the CI
of mortality reduction and overdiagnosis estimates. Estimates
were made for both invited and screened women.
Several sensitivity analyses were conducted. First, we
assumed a theoretical 10% increase in the cumulative risk of
breast cancer due to DCIS (instead of the observed 2.8%).
Second, we used the NORDCAN rates for 1990 before any
screening started in Denmark, showing cumulative risks of
6.9% for breast cancer (invasive1DCIS) and 3.4% for breast
cancer death. Hence, the expected numbers of breast cancers
and breast cancer deaths in which screening may had an
effect were 69 and 22 per 1,000 women aged 50–79. Third,
rates of breast cancer incidence and mortality might have
progressed over time independently of screening. Simulations,
using the observed trend in Denmark from 1970 to 1990,7 of
a 30% increase in cumulative incidence and a 15% increase
in cumulative mortality were applied to the 1990 rates. In
this estimation, the cumulative risk of breast cancer (invasi-
ve1DCIS) was 8.8%, and the cumulative risk of death from
breast cancer was 3.9%. Hence, the expected numbers of
breast cancers and breast cancer deaths potentially affected
by screening were 88 and 26 per 1,000 women aged 50–79.
Figure 1. Benefits and harms of breast cancer screening.
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Results
For every 1,000 women aged 50 invited to breast cancer screen-
ing biennially to age 69 and followed until age 79, we estimated
that 5.4 (523.1 3 0.234) breast cancer deaths would be pre-
vented and 2.1 (590.6 3 0.023) cases would be overdiagnosed,
under the observed scenarios in Denmark of a breast cancer
mortality reduction of 23.4 and 2.3% of the breast cancer cases
being overdiagnosed (Fig. 2). The estimated beneﬁt-to-harm
ratio for invited women was 2.6 (55.4/2.1) (Table 2).
For screened women, these numbers were 7.5 (5 23.5 3
0.321) breast cancer deaths prevented, 3.0 (590.4 3 0.033)
cases overdiagnosed, and a beneﬁt-to-harm ratio of 2.5 (Fig.
2, Table 2).
The sensitivity analyses, assuming a theoretical increase of
breast cancer incidence of 10% due to DCIS, resulted in an
expected cumulative risk of breast cancer in absence of
screening of 95.6 per 1,000 women aged 50–79. Among
invited women, this led to 2.2 overdiagnosed cases, giving a
beneﬁt-to-harm ratio of 2.5 (55.4/2.2). Among screened
women, it gave 3.1 overdiagnosed cases, resulting in a ratio
of 2.4 (57.5/3.1).
Using rates from 1990 resulted in 5.1 breast cancer deaths
prevented, 1.6 overdiagnosed cases, and a beneﬁt-to-harm ratio
of 3.2 for invited women. For screened women, 7.1 breast can-
cer deaths would be prevented and 2.3 women would be over-
diagnosed, leading to a ratio of 3.1. Lastly, simulating an
increase in the 1990 rates of 30% for cumulative breast cancer
incidence and of 15% for cumulative breast cancer mortality
led to 6.1 breast cancer deaths prevented, 2.0 overdiagnosed
cases, and a beneﬁt-to-harm ratio of 3.1 for invited women.
For screened women, 8.3 breast cancer deaths would be pre-
vented and 2.9 women overdiagnosed, leading to a ratio of 2.9.
Discussion
Main findings
Among women invited to breast cancer screening in Den-
mark, the beneﬁt-to-harm ratio was 2.6; meaning that 2–3
women would be prevented from breast cancer death for
every woman overdiagnosed. Hence, in term of number of
breast cancer deaths prevented, the beneﬁt was two to three
times the harm in terms of overdiagnosed cases. An alterna-
tive way of expressing the results is that the number of
women needed to be invited for screening in order to prevent
one breast cancer death was 185. The number of women
needed to be screened to prevent one breast cancer death
was 133. The sensitivity analyses showed a beneﬁt-to-harm
ratio ranging from 2.4 to 3.2 for invited and screened
women. Our estimated beneﬁt-to-harm ratios were similar
for invited and screened women, as the effects of screening
on breast cancer incidence and mortality changed propor-
tionally for invited and screened women.
Strength and weakness
With the comprehensive register data and the long-time
interval between implementation of screening in
Table 1. Estimation of cumulative risk of breast cancer (BC) and BC death for every 1,000 women in the Danish breast cancer screening pro-
gramme aged 50, and followed until age 79
Estimation
For 1,000 women invited
biennially from 50 to 69 years
For 1,000 women screened
biennially from 50 to 69 years
Breast cancer
BC (invasive and DCIS) from 50 to 79 years based on
age-specific 1996-2000 incidence rates
91 91
Expected BC, corrected for early start programmes (A) 90.6
(A591 – (0.2 3 A 3 0.023))
90.4
(A591 – (0.2 3 A 3 0.033))
Breast cancer death
BC death (invasive and DCIS) from 50 to 79 years
based on age-specific 1996–2000 mortality rates
34 34
BC death, potentially affected by screening 22 22
Expected BC death, corrected for early start
programmes (B)
23.1
(B5221(0.2 3 B 3 0.234))
23.5
(B5221(0.2 3 B 3 0.321))
Figure 2. Estimated number of breast cancer deaths prevented and
overdiagnosed cases for every 1,000 women aged 50, invited to
screening or screened biennially in the Danish breast cancer screen-
ing programme to age 69, and followed until age 79. Estimates
were based on 23.4% reduction in mortality from breast cancer
(invasive1DCIS) and 2.3% overdiagnosis for invited women;3–5
figures were 32.1 and 3.3% for screened women.3–5 Estimates were
applied to observed incidence of and mortality from breast cancer
in Denmark in 1996–2000 (women aged 50–79 years).7
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Copenhagen/Funen and in the rest of the country, Denmark
offers an ideal setting of estimation of the beneﬁt-to-harm
ratio of breast cancer screening. The mortality reduction3,4
and overdiagnosis5 used in our estimations came from obser-
vational studies following cohorts of women offered and not
offered screening; using incidence-based mortality analysis;
controlling for pre-screening differences between regions; and
including a long post-screening follow-up time. The mortality
reduction3,4 had been estimated using the follow-up analysis
found in the Swedish randomized controlled trials to give the
most conservative estimate.8 The overdiagnosis5 was esti-
mated without the youngest cohorts due to their short post-
screening follow-up time, which might have resulted in a
slight underestimation.
In the analyses of breast cancer mortality and overdiagno-
sis, both area and time had been controlled for. But, it was
assumed that in the absence of screening, the breast cancer
mortality and the breast cancer incidence would over time
have changed to the same extent in screening and non-
screening area. In statistical terms this means that there was
no interaction. In analyses of breast cancer mortality, this
assumption was considered reasonable based on the time
trends in breast cancer mortality in the pre-screening period.9
In the analysis of overdiagnosis, Njor et al.5 tested this
assumption and observed for the oldest birth cohorts an
interaction between area and time period in the Copenhagen
data. Breast cancer incidence data from these birth cohorts
prior to screening age was used to correct for this interaction.
No interaction was found in the Funen data.
Despite the use of the national Danish data, the point esti-
mates of reduction in breast cancer mortality of 23.4% and of
overdiagnosis of 2.3% came with some uncertainty. For
reduction in breast cancer mortality the 95% CI was from 11
to 34.3% and for overdiagnosis it was from 0 to 8%. If we
combined these into the worst scenario for the beneﬁt-to-
harm ratio, it became 0.3 (52.5/7.2), thus indicating almost
three extra breast cancer cases diagnosed for each breast can-
cer death prevented. The best scenario for the beneﬁt-to-
harm ratio became 8.1 if we used only the upper limit of the
CI for reduction in breast cancer mortality. This means eight
breast cancer deaths prevented for each overdiagnosed case.
However, none of these extremes seemed realistic, so we
considered the point estimate to be the best representation of
the beneﬁt-to-harm ratio in Denmark.
The outcomes of breast cancer screening in Denmark
were reported also in other studies. Jørgensen et al. “were
unable to detect any effect of the Danish screening pro-
grammes on breast cancer mortality.”10 This study was based
on routine breast cancer mortality data including deaths in
women diagnosed before screening started. Furthermore, the
authors focused on the similarity of the average annual
changes (equal to the slopes) in the trends of death rates in
screening and non-screening regions from pre-and post-
screening periods. They ignored a statistically signiﬁcant
change in the relative level of the trends occurring between
their pre-and post-screening periods. Jørgensen et al.
reported that “one in every three women aged 50 to 69 years
diagnosed with breast cancer was overdiagnosed.”11 Estima-
tion was only based on rates of non-advanced tumors
because “there was no clear compensatory decrease in the
incidence of advanced cancer in older women” (i.e., women
aged 70 to 84 years). However, almost half of the observa-
tions in the age-group 70–84 years were from women never
invited to screening or still invited despite having passed the
age of 70 years. These women could not contribute to the
compensatory dip. Therefore, we did not include these stud-
ies in our estimations.
We present a beneﬁt-to-harm ratio derived from simple
age-speciﬁc breast cancer incidence and mortality rates from
Denmark. A more complex analysis using individual level
data might have led to different results, but the simplicity of
the interpretation the possibility to compare with other stud-
ies might have been lost.
Moreover, our results focused only on breast cancer mor-
tality reduction and overdiagnosis. But other beneﬁts and
harms of mammography screening should be considered in
evaluating a population-based screening programme. Other
beneﬁts include more conservative treatment and the positive
psychological effect of knowing that a negative test is associ-
ated with a reduced breast cancer risk. Other harms of mam-
mography screening include longer time as a cancer patient
due to the lead time, false positive and false negative tests.
Further harms to be considered are radiation exposure and
negative psychological effects in terms of anxiety about
Table 2. Estimates of the benefit-to-harm ratio in the Danish breast cancer screening programme
For every 1,000 women aged 50,
invited to screening biennially to
age 69, and followed until age 79
For every 1,000 women aged 50,
screened biennially to age 69,
and followed until age 79
Estimate of mortality reduction using3,4 23.4% (95% CI: 11 to 34.3%) 32.1%*
Estimate of overdiagnosis using5 2.3% (95% CI: 23 to 8%) 3.3%*
Number of breast cancer deaths prevented 5.4 (2.5 to 8.1) 7.5
Number of overdiagnosed cases 2.1 (1 to 7.2) 3.0
Benefit-to-harm ratio 2.6 2.5
Note:
*Confidence intervals not reported in the original studies.
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waiting for the mammogram report and the false reassurance
to women later diagnosed with interval cancers (Fig. 1).
Comparison with other studies
Our beneﬁt-to-harm ratio was more in favor of screening
than the results from the Marmot report12 and from the
Norwegian Breast Cancer Screening Program,2 but similar to
results reported by Duffy et al.13 and the EUROSCREEN
group.1
The Marmot report12 used results from the randomized
controlled trials (RCTs) to estimate the beneﬁt and risk of
breast cancer screening. For every 1,000 women invited to
screening, 4.3 breast cancer deaths would be prevented and
12.9 cases would be overdiagnosed. Combining these esti-
mates would lead to a beneﬁt-to-harm ratio of 0.33. Similarly,
for every 1,000 women screened, 5.6 breast cancer deaths
would be prevented and 16 cases would be overdiagnosed,
leading to a ratio of 0.35. While the impact of screening on
breast cancer mortality was estimated based on all nine
RCTs, overdiagnosis was estimated only from the three RCTs
“that did not systematically screen the control group at the
end of the screening period.”12 However, even these RCTs
were not well suited for estimation of overdiagnosis.14 In the
Malm€o RCT, the excess cumulative breast cancer incidence
derived exclusively from women screened on average to age
76.5, which left limited time for post-screening follow-up.
The two Canadian RCTs targeted women aged 40–4915 and
50–59 years,16 but shortly after the trials stopped, service
screening was implemented for women aged 50–69 in the
majority of Canadian provinces from which the trial popula-
tions were recruited.17
Hofvind et al.2 presented estimates from the Norwegian
Breast Cancer Screening Program. For every 1,000 invited
women, 4.0 breast cancer deaths would be prevented and
8.9–10.6 cases overdiagnosed, giving a beneﬁt-to-harm ratio
of 0.38–0.45. For screened women, the numbers were 5.7,
8.2, and a ratio of 0.7. The impact of screening on breast
cancer mortality was estimated from a Norwegian study
showing a 28% reduction for invited women.18 The same
study gave an estimate of 36.8% for screened women,18 while
another study gave an estimate of 43% based on comparison
of screened with non-screened women.19 For screened
women, an overdiagnosis percentage was combined from two
studies. One from the Norwegian screening programme
where excess cases in regular screened women during screen-
ing1 deﬁcit cases in ever screened in post-screening were
compared with numbers in never screened women giving an
estimate of 18.5%.20 The second estimate of 7% came from
comparison of programme-screened with outside screen-
ed1 never screened women in the Norwegian Women and
Cancer Study.21
The Danish and Norwegian screening programmes are
very similar. Therefore, it is noteworthy that while the esti-
mated impact on breast cancer mortality was almost the
same in the two countries, the Norwegian estimates of
overdiagnosis based on approximations were considerably
higher than the Danish estimate based on the observed excess
cumulative incidence. While both the Danish and the Norwe-
gian estimates divide the number of overdiagnosed breast
cancer cases with all breast cancer cases diagnosed in the
follow-up period, there are, nevertheless, methodological dif-
ferences between the two estimates of overdiagnosis. The
Danish estimate is the only one based on observational data
with enough time for sufﬁcient post-screening follow-up,
while the estimate from Norway was based predominantly on
observations from the time during or shortly after end of
invitation to screening.
Duffy et al.13 presented data from the Swedish Two-
County RCT and the UK Breast Screening Programme in
England. For every 1,000 screened women, the Two-County
RCT found 8.8 breast cancer deaths would be prevented. The
control group in this RCT was offered screening after the
end of the trial. To estimate overdiagnosis, Duffy et al.
excluded breast cancer cases diagnosed during the prevalence
screen of the control group and estimated 4.3 extra breast
cancer cases diagnosed per 1,000 women in the intervention
group as compared with the control group. This gave a
beneﬁt-to-harm ratio of 2.0. For England, breast cancer inci-
dence and mortality rates from 1974–1988 were used to pre-
dict the expected number in the absence of screening after
the start of screening in 1989. In 1995–2004, 28% fewer
breast cancer deaths were observed in women aged 50–69
years, as compared with the expected based on the rates for
1974–1988, and adjusted for changes over time in the youn-
ger and older age-groups. This translated into 5.7 prevented
breast cancer deaths per 1,000 screened women. Overdiagno-
sis was estimated as the observed number of cases in 1989–
2003 in women aged 451 compared with the expected num-
ber based on pre-1988 rates for the same age-groups and
standardized to the age-group below 45 years. This resulted
in 2.3 overdiagnosed cases per 1,000 screened women. This
number might, however, be too high as screening was imple-
mented only gradually for women aged 50–64 years in 1989–
1993, and women aged 65–69 years were offered screening in
2002–2003. Limited time had therefore been available for
accumulation of post-screening person years. The English
data resulted in a beneﬁt-to-harm ratio of 2.5.
The EUROSCREEN estimates were based on joint data
from the European service screening programmes available in
2012.1 For screened women, the reduction in breast cancer
mortality was 38% in incidence-based mortality studies and
48% in the case-control, giving 7–9 prevented breast cancer
deaths for 1,000 screened women. Overdiagnosis had been
assessed with various methodologies, providing a joint esti-
mate of 6.5%, giving four extra cases for 1,000 screened
women. The beneﬁt-to-harms ratio thus became 1.8–2.3.
The data and methodology used in the beneﬁt-to-harm
studies are summarized in the Supporting Information Table
1. Estimates of overdiagnosis are sensitive to methodology.22
We used only estimates, where there was correspondence
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between the percentage of overdiagnosis reported and the
age-group to which this percentage was applied. In the Mar-
mot report, the numbers were given for women aged 50 years
and followed for 20 years.12 In the Two County Study for
women aged 50–69 years at randomization,13 in the English
data for women aged 45 and above,13 while both the Norwe-
gian2 and the EUROSCREEN1 studies used data for women
aged 50–79 years, as we did.
The reported beneﬁt-to-harm ratios varied due to differ-
ences in number of prevented breast cancer deaths and/or
number of overdiagnosed cases. The reductions in breast can-
cer mortality varied from 20% in the Marmot report12 to
32% from the Two County Study.13 This reﬂected that the
Marmot report used all RCTs, including the two Canadian
outliers,15,16 and that the Two County Study was the single
RCT with the largest reduction in breast cancer mortality.
The proportion of overdiagnosed cases varied from 2.3% in
the Danish data to 15.6% in the Norwegian data. To generate
valid data on overdiagnosis, high quality RCTs with no
screening of women in the control arm at any point and
with long-follow-up would be required. Unfortunately, such
RCT data are not available. Previous studies of overdiagnosis
have, therefore, used various modeling (Two County Study)
and/or approximation (Norway) or short-term observational
data (England).
In order to implement truly shared decision making in
breast cancer screening, information is requested on beneﬁts
and harms of screening. Our comparison of the reported
ratios illustrated considerable variation. The difference
between the ratios for invited women of 0.4 for Norway and
2.6 for Denmark is probably more a reﬂection of the accu-
racy of the underlying estimates than of the actual screening
programmes. Observational data rely on assumption about
what does and what does not vary over time and geography,
and/or modeling to deal with the uncertainties. Therefore, all
beneﬁt-to-harm ratios estimated from available observational
data should be used cautiously.
Conclusions
Our study estimated that for invited women the beneﬁt-to-
harm ratio of the Danish breast cancer screening programme
was 2.6. Among 1,000 women invited to screening from age
50 and followed until 79, 2–3 women would be prevented
from dying from breast cancer for every woman overdiag-
nosed with invasive breast cancer or DCIS.
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